Advanced Biomed Inc..
ADVB.US | Manufacture of medical and dental instruments and supplies
Advanced Biomed Inc. is a biotechnology company focused on the research, development, and commercialization of innovative medical devices and therapies. The company's primary focus is on developing and marketing advanced wound care products, surgical sealants, and drug delivery systems. Their produc...Show More
Better Health for All
20
Advanced Biomed Inc.'s entire business is devoted to health improvement through the development and commercialization of medical devices and technologies for early cancer detection, diagnosis, and treatment. The company has no products with significant negative health impacts. It raised $6.56 million in its IPO in March 2025, with proceeds allocated to IVD clinical research, chip design, facility upgrades, and market expansion.
1
The company focuses on preventative health measures through the development of early cancer screening kits, such as the A+LCGuard Lung Cancer Early Screening Kit, which achieved 96% sensitivity and 99.9% specificity in a study of 123 patients.
2
The company plans to start clinical research for A+LCGuard by the end of June 2025, with the protocol expected to pass ethical review and receive approval by the end of September 2025.
3
Fair Money & Economic Opportunity
0
Advanced Biomed Inc. is a biotechnology company focused on medical devices and therapies.
1
The company does not offer lending or deposit services to consumers, nor does it manage customer finance data or provide debt products.
2
Therefore, there is no evidence of consumer credit products, associated APRs, fee structures, or revenue from high-cost financial products. The company does not have a loan/insurance book or dedicated inclusion programs.
3
Furthermore, there is no information regarding financial literacy initiatives, customer debt burden ratios, or financial service access points in specific geographic regions.
4
The company's products are medical devices, not financial products requiring disclosure or explanation in the context of financial literacy or product simplicity.
5
The company reported net losses for Q3 2025 ($386,901) and for the year ended June 30, 2025 ($3.3 million), indicating no profits available for reinvestment in community finance.
6
Fair Pay & Worker Respect
0
No quantitative data was provided in the articles to assess Advanced Biomed Inc. against any of the KPIs for Fair Pay & Worker Respect.
1
Both articles explicitly state that no specific data points are available for metrics such as living wage coverage, CEO-to-median-employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.
2
Fair Trade & Ethical Sourcing
0
No specific, quantitative data points were found in the provided articles regarding Advanced Biomed Inc.'s performance on any of the Fair Trade & Ethical Sourcing KPIs. The articles discuss general concepts of provenance tracking and blockchain technology in supply chains but do not provide any company-specific evidence for ADVB.US related to fair trade certifications, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.
Honest & Fair Business
0
The provided article details company executives, board members, and recent appointments but does not contain any specific, quantitative data points for regulatory fines, transparency scores, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflict percentages, anti-corruption policies, or third-party verification.
1
Therefore, no KPIs can be scored based on the available evidence.
Kind to Animals
0
No specific, concrete evidence was found in the provided articles regarding Advanced Biomed Inc.'s performance across any of the 'Kind to Animals' KPIs. The articles discuss general industry trends, market sizes for non-animal testing, regulatory changes, and activities of other companies, but do not provide any data points directly attributable to Advanced Biomed Inc. concerning cruelty-free certifications, alternative testing usage, humane certifications, wildlife conservation, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy or volume, innovation investment, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement.
No War, No Weapons
0
No specific, concrete data points were found in the provided articles to assess Advanced Biomed Inc. against any of the 'No War, No Weapons' KPIs.
1
Both articles explicitly state that sustainability data or data relevant to this ethical value is unavailable for ADVB.US.
2
Planet-Friendly Business
-30
Advanced Biomed Inc. (Philips) has had its entire value chain CO₂ emissions reduction targets approved by the Science Based Targets initiative (SBTi), including defined interim checkpoints.
1
The company achieved carbon neutrality in Scope 1 and 2 emissions by 2020.
2
By the end of 2022, 40% of its suppliers (based on spend) were committed to science-based targets.
3
Respect for Cultures & Communities
0
No evidence available to assess Advanced Biomed Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Advanced Biomed Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Advanced Biomed Inc.'s performance on any of the Zero Waste & Sustainable Products KPIs. The articles focus on the company's IPO and research and development in microfluidic biochip technologies and tumor diagnostics/treatment, without mentioning waste management, product recyclability, packaging sustainability, or any other related initiatives.
1